177 related articles for article (PubMed ID: 32999004)
1. Tumor Cell-Derived TGFβ1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA.
Wu P; Geng B; Chen Q; Zhao E; Liu J; Sun C; Zha C; Shao Y; You B; Zhang W; Li L; Meng X; Cai J; Li X
Cancer Immunol Res; 2020 Dec; 8(12):1470-1484. PubMed ID: 32999004
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J
Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating CD39
Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
5. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.
Park BV; Freeman ZT; Ghasemzadeh A; Chattergoon MA; Rutebemberwa A; Steigner J; Winter ME; Huynh TV; Sebald SM; Lee SJ; Pan F; Pardoll DM; Cox AL
Cancer Discov; 2016 Dec; 6(12):1366-1381. PubMed ID: 27683557
[TBL] [Abstract][Full Text] [Related]
6. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.
Giraldo NA; Becht E; Pagès F; Skliris G; Verkarre V; Vano Y; Mejean A; Saint-Aubert N; Lacroix L; Natario I; Lupo A; Alifano M; Damotte D; Cazes A; Triebel F; Freeman GJ; Dieu-Nosjean MC; Oudard S; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2015 Jul; 21(13):3031-40. PubMed ID: 25688160
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of CD45RO+CD8+ T cells is a diagnostic and prognostic biomarker for clear cell renal cell carcinoma.
Wu K; Zheng X; Yao Z; Zheng Z; Huang W; Mu X; Sun F; Liu Z; Zheng J
Aging (Albany NY); 2021 May; 13(10):14304-14321. PubMed ID: 34016791
[TBL] [Abstract][Full Text] [Related]
8. Machine learning-based integration develops a stress response stated T cell (Tstr)-related score for predicting outcomes in clear cell renal cell carcinoma.
Yang S; Han Z; Tan Z; Wu Z; Ye J; Cai S; Feng Y; He H; Wen B; Zhu X; Ye Y; Huang H; Wang S; Zhong W; Deng Y
Int Immunopharmacol; 2024 May; 132():112017. PubMed ID: 38599101
[TBL] [Abstract][Full Text] [Related]
9. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
10. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
11. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
Qiu X; Gu Y; Ni Y; Li Q
Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
15. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
16. Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma.
Hua X; Chen J; Su Y; Liang C
Aging (Albany NY); 2020 Feb; 12(3):2302-2332. PubMed ID: 32028264
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
[TBL] [Abstract][Full Text] [Related]
18. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
[TBL] [Abstract][Full Text] [Related]
19. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.
MacFarlane AW; Jillab M; Plimack ER; Hudes GR; Uzzo RG; Litwin S; Dulaimi E; Al-Saleem T; Campbell KS
Cancer Immunol Res; 2014 Apr; 2(4):320-31. PubMed ID: 24764579
[TBL] [Abstract][Full Text] [Related]
20. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]